Literature DB >> 2139697

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.

A Nagler1, L L Lanier, J H Phillips.   

Abstract

The majority of human NK cells express low affinity IgG Fc receptors (CD16+), whereas a minor subset of NK cells lack Fc receptor expression (CD16-). In contrast to CD16+ NK cells that express only p75 IL-2 receptors, CD16- NK cells constitutively co-express both p75 and p55 IL-2 receptors in vivo and preferentially respond to low concentrations of IL-2 with increased cytolytic activation and proliferation. Scatchard analysis demonstrated the presence of approximately 1,200 high affinity (approximately 25 pM kD) and approximately 9,600 intermediate affinity (approximately 2 nM kD) IL-2 receptors on CD16- NK cells. CD16+ NK cells expressed only a single intermediate affinity IL-2 receptor of approximately 1.9 nM kD (approximately 9,000 sites per cell). The IL-2 binding data thus substantiated the phenotypic and functional studies and definitively show that the differential responsiveness of CD16- and CD16+ NK cells to IL-2 is manifested through different affinity IL-2 receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139697      PMCID: PMC2187903          DOI: 10.1084/jem.171.5.1527

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells.

Authors:  A L Jackson; H Matsumoto; M Janszen; V Maino; A Blidy; S Shye
Journal:  Clin Immunol Immunopathol       Date:  1990-01

2.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.

Authors:  L L Lanier; A M Le; C I Civin; M R Loken; J H Phillips
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

3.  Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.

Authors:  T M Ellis; R I Fisher
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

4.  Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.

Authors:  M Tsudo; F Kitamura; M Miyasaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Comparative studies of human FcRIII-positive and negative natural killer cells.

Authors:  A Nagler; L L Lanier; S Cwirla; J H Phillips
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

6.  Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.

Authors:  L L Lanier; C J Benike; J H Phillips; E G Engleman
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

7.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

Authors:  J H Phillips; B T Gemlo; W W Myers; A A Rayner; L L Lanier
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

8.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  Activation of natural killer cells via the p75 interleukin 2 receptor.

Authors:  J H Phillips; T Takeshita; K Sugamura; L L Lanier
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

View more
  51 in total

1.  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Authors:  T A Fehniger; E M Bluman; M M Porter; E Mrózek; M A Cooper; J B VanDeusen; S R Frankel; W Stock; M A Caligiuri
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells.

Authors:  Philip J Norris; Dale F Hirschkorn; Deborah A DeVita; Tzong-Hae Lee; Edward L Murphy
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

3.  Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30).

Authors:  E Mavoungou; M K Bouyou-Akotet; P G Kremsner
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

4.  Low-dose IL-2 induces CD56bright NK regulation of T cells via NKp44 and NKp46.

Authors:  S T Loughran; P A Power; S L McQuaid; P Maguire; A Szczygiel; P A Johnson
Journal:  Clin Exp Immunol       Date:  2020-02-13       Impact factor: 4.330

5.  Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.

Authors:  Megan C Duggan; Amanda R Campbell; Elizabeth L McMichael; Kallan S Opheim; Kala M Levine; Neela Bhave; Michelle C Culbertson; Tiffany Noel; Lianbo Yu; W E Carson
Journal:  Oncoimmunology       Date:  2017-10-16       Impact factor: 8.110

6.  Changes in natural killer cells, the CD57CD8 subset, and related cytokines in healthy aging.

Authors:  S E McNerlan; I M Rea; H D Alexander; T C Morris
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

7.  Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.

Authors:  L Matera; G Bellone; J J Lebren; P A Kelly; E L Hooghe Peters; P F Di Celle; R Foa; M Contarini; G Avanzi; V Asnaghi
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

Review 8.  Exercise and the immune system. Natural killer cells, interleukins and related responses.

Authors:  R J Shephard; S Rhind; P N Shek
Journal:  Sports Med       Date:  1994-11       Impact factor: 11.136

9.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

10.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Authors:  J W Gratama; R J Bruin; C H Lamers; R Oosterom; E Braakman; G Stoter; R L Bolhuis
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.